Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-Resistant Prostatic Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01540071
What this trial is testing

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
Io Therapeutics 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Not applicableStudy completedNCT02669147
What this trial is testing

Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC

Who this might be right for
Castration Resistant Prostate Cancer (CRPC)
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 160
Early research (Phase 1)Study completedNCT04786847
What this trial is testing

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 30
Not applicableStudy completedNCT00455624
What this trial is testing

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

Who this might be right for
Prostate Cancer
Massachusetts General Hospital 60
Testing effectiveness (Phase 2)Ended earlyNCT01996696
What this trial is testing

Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate

Who this might be right for
Prostatic Neoplasm
AHS Cancer Control Alberta 83
Testing effectiveness (Phase 2)Looking for participantsNCT06039371
What this trial is testing

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
University of Washington 69
Early research (Phase 1)Study completedNCT03575819
What this trial is testing

FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Fortis Therapeutics, Inc. 56
Testing effectiveness (Phase 2)Study completedNCT00666666
What this trial is testing

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateStage IV Prostate Cancer
National Cancer Institute (NCI) 55
Post-approval studies (Phase 4)Active Not RecruitingNCT03016741
What this trial is testing

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+2 more
Northwestern University 100
Testing effectiveness (Phase 2)Ended earlyNCT02379390
What this trial is testing

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
Sanofi 8
Post-approval studies (Phase 4)Study completedNCT02918968
What this trial is testing

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Astellas Pharma Inc 206
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Post-approval studies (Phase 4)Looking for participantsNCT05348876
What this trial is testing

Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 50
Testing effectiveness (Phase 2)Study completedNCT02217566
What this trial is testing

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 46
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT02097303
What this trial is testing

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Who this might be right for
Prostate Cancer
Carolina Research Professionals, LLC 36
Early research (Phase 1)Ended earlyNCT04279561
What this trial is testing

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center 9
Early research (Phase 1)Study completedNCT02814669
What this trial is testing

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Who this might be right for
Castrate-Resistant Prostate Cancer
Hoffmann-La Roche 45
Testing effectiveness (Phase 2)Study completedNCT04381832
What this trial is testing

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-ResistantAndrogen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic Neoplasms+1 more
Arcus Biosciences, Inc. 173
Next Page